![[특징주]’Disappointment of Corona 19 Treatment’](https://newsimg.sedaily.com/2021/01/15/22H9KFB9ZX_1.jpg "[특징주]’Disappointment of Corona 19 Treatment’")
Celltrion fell by 3%, Celltrion Pharmaceutical fell by 4%
Continued weakness after plunging the previous day due to lack of expectation of treatment effect
viewer
Celltrion (068270) The effects of the treatment of Corona 19 were weaker at the beginning of the market on the 15th, as the effect of the treatment of Corona 19 did not meet market expectations.
As of 9:32 am on the day, Celltrion is trading at 344,000 won, down 2.41% (8,500 won) from the previous day in the securities market.
At the same time on KOSDAQ Celltrion Healthcare (091990)Is 151,400 won, down 2.89% (4,500 won) from the previous day, Celltrion Pharmaceutical (068760)Silver is trading at 188,400 won, down 4.2% (8,700 won).
It is analyzed as the cause of the weakness in the stock price that Celltrion’s treatment effect of the Corona 19 treatment’Rekironaju’ falls short of market expectations.
According to data from Celltrion’s Phase 2 clinical trial for COVID-19, which was released on the 13th, Rekironaju was found to reduce the incidence of severely ill patients requiring inpatient treatment by 54% for all patients and 68% for moderately ill patients over 50.
However, it was regrettable that the P value, a statistically significant index as a treatment, did not reach 0.05, which measures the effect except for patients in their 50s.
In the case of Rekirona, the P value was 0.196 for all patients, 0.105 for patients with moderate pneumonia, and 0.0418 for moderate patients in their 50s. Excluding the elderly and moderately ill patients, the effect is greatly reduced.
/ Reporter Yang Sa-Rok [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >